Five things for pharma marketers to know: Wednesday, February 22, 2017

Five things for pharma marketers to know: Wednesday, February 22, 2017

Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead

Deloitte taps Havas Lynx's Mickelberg as MD

Deloitte taps Havas Lynx's Mickelberg as MD

Dennis Urbaniak has also been named chief digital officer at Havas Lynx.

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

How VAYA Pharma used Facebook ads for its ADHD campaign

How VAYA Pharma used Facebook ads for its ADHD campaign

The campaign would require a two-fold approach: Facebook link ads and Facebook Audience Network.

WebMD considers sale or merger

WebMD considers sale or merger

Drugmakers are becoming much more cautious with their budgets, WebMD executives said.

Five things for pharma marketers to know: Friday, February 17, 2017

Five things for pharma marketers to know: Friday, February 17, 2017

Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March

Five things for pharma marketers to know: Thursday, February 16, 2017

Five things for pharma marketers to know: Thursday, February 16, 2017

The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents

Industry hires and promotions: February 2017

Industry hires and promotions: February 2017

Novo Nordisk appoints new CEO, and more people moves for you to know about

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

OPINION

Newsletters